Ultra-High Concentration Nitric Oxide (UNO) Enhances Anti-CTLA-4 Treatment Activity and Induces a Durable Anti-Tumor Immune Response

Yogev Sela1, Matan Goldstein2, Jedidiah M. Monson2, Hila Confinio1, Matt Johnson2, Selena Chaisson2, Amir Avniel3,4, Mark D. Pegram5

1Beyond Cancer, Rehovot, Israel 2Beyond Cancer, Atlanta, GA, USA 3Beyond Air, Garden City, NY, USA 4Beyond Air, Rehovot, Israel 5Stanford University, Stanford, CA, USA

AARC-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
October 11-15, 2023

Background

We previously demonstrated that intratumoral administration of ultra-high concentration nitric oxide (UNO) favorably augments the immune response in CT26 tumor-bearing mice. Five to 14 days after treatment, antigen-presenting cells inform the adaptive immune response by presenting antigens to immature T cells. At day 14, treatment with 50,000 ppm UNO resulted in higher levels of T-cell, B-cell, macrophage, and dendrocyte infiltration compared to both nitrogen and 20,000 ppm UNO (Figure 1).

Methods

In this study, we assessed the systemic and local tumor response of CD8+ T-cells, T-cells, and systemic central memory T-cells, recognizing the AH-1 antigen following 50,000 or 100,000 ppm UNO and 5mg/kg anti-mCTLA-4 treatment given for 2 to 5 doses in CT26 (mouse colon cancer model) tumor-bearing BALB/c mice.

Systemic T-cell Response Following UNO and Anti-mCTLA-4

The immunodominant AH-1 antigen is associated with anti-tumor immune response to CT26 tumors. A systemic antigen-specific and central memory (CM) response is observed by day 7 (Figure 4A and 4B). Durable upregulation in systemic AH-1-specific T-cells is observed in cured mice at day 55 (Figure 4C) and day 100 (Figure 4D).

Conclusions

Intratumorally, at day 5 post-UNO treatment, T-helper and T-cytotoxic cells are significantly increased in the combination arm relative to the anti-mCTLA-4 arm alone. Systemically, UNO stimulates a significantly higher central memory T-cell response than anti-mCTLA-4 and synergizes with this drug by day 7 to generate a higher antigen-specific T-cell response. Durable upregulation in systemic AH-1-specific T-cells is still seen at day 55 post-therapy and has been confirmed as late as day 100. A clinical study investigating intratumoral administration of UNO has been initiated (BA-ONC-01 clinicaltrials.gov NCT identifier: NCT05351502).

Figure 1: Timeline Showing the MOA Following UNO Treatment

Figure 2: Study Scheme

Figure 3: Tumor T-cell Levels Following UNO and Anti-mCTLA-4 Treatment at Day 5. (A) Tumor T-cytotoxic cells (B) Proliferating Tumor T-helper cells, (C) IFNγ+ expressing tumor T-helper cells. *p<0.05, ***p<0.0001

Figure 4: Systemic Antigen-specific and Memory T-cells Following UNO and Anti-mCTLA-4 Treatment at Days 7, 55, and 100. (A) Blood AH-1 T-cells at day 7, (B) Blood CM T-cells at day 7, (C,D) Blood AH-1-specific T-cells (Left), and mouse survival (Right) at day 55 and 100. *p<0.05, **p<0.01